TUESDAY, May 2, 2023 (HealthDay News) — Many common household products emit airborne toxins that can harm your health in ways up to and including cancer, a new study reports. Dozens of different types of consumer products contain toxic volatile organic compounds (VOCs), chemicals that escape as gases and accumulateContinue Reading

TUESDAY, May 2, 2023 (HealthDay News) — Teens who are abused by a romantic partner may suffer long-lasting repercussions, and this is especially true for girls, a new analysis finds. Investigators who reviewed 38 studies concluded that teenage dating violence was linked to a higher risk for additional relationship violenceContinue Reading

THURSDAY, April 27, 2023 (HealthDay News) — Jobs that regularly expose you to certain chemicals appear to steadily increase your risk of pancreatic cancer, a new analysis reports. People with more than 20 years of exposure to some chemical agents had a 39% increased risk of pancreatic cancer, compared withContinue Reading

THURSDAY, April 13, 2023 (HealthDay News) — It sounds like the stuff of a vampire novel, but for people with a group of rare genetic disorders, exposure to sunlight can cause excruciating pain. Now, an experimental medication is showing promise for helping them better tolerate the light of day. InContinue Reading

WEDNESDAY, April 12, 2023 (HealthDay News) — Financial stress and work lost to cancer treatment affects patients and their partners alike. Partners also experienced pain, fatigue and sleep issues owing to these fiscal worries, a new study found. “We know that financial toxicity or hardship is a significant effect ofContinue Reading

WEDNESDAY, April 5, 2023 (HealthDay News) — A therapy that bolsters the immune system may not only help certain cancer patients live longer, but better, a new study finds. The treatment, called chimeric antigen receptor (CAR) T-cell therapy, is used to fight certain types of blood cancer — including leukemiaContinue Reading

MONDAY, April 3, 2023 (HealthDay News) — An experimental targeted drug could provide a fresh chance for people with recurring head and neck cancer that has grown resistant to other treatments, a new clinical trial says. Ficlatuzumab used in combination with the already approved targeted drug cetuximab (Erbitux) significantly improvedContinue Reading